Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:methylphenidate
|
| gptkbp:approvalYear |
2012
|
| gptkbp:ATCCode |
N06BA04
|
| gptkbp:brand |
methylphenidate hydrochloride
|
| gptkbp:contraindication |
glaucoma
use with MAO inhibitors tics hypersensitivity to methylphenidate |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II
|
| gptkbp:duration |
up to 12 hours
|
| gptkbp:form |
gptkb:water
extended-release oral suspension |
| gptkbp:halfLife |
2-4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quillivant XR
|
| gptkbp:indication |
gptkb:attention_deficit_hyperactivity_disorder
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
gptkb:Tris_Pharma |
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
abdominal pain
increased heart rate nervousness insomnia decreased appetite |
| gptkbp:bfsParent |
gptkb:methylphenidate
|
| gptkbp:bfsLayer |
6
|